SEC Tracker
Get the app

Larimar Therapeutics LRMR

Larimar Therapeutics shares cash position and FDA submission

Larimar Therapeutics (LRMR) filed an 8-K with the SEC on Nov 9, 2026, 4:09 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 8.01 Other events

Form
8-K
Filed
Importance
Major
  1. As of September 30, 2026, $128.7 million in cash, cash equivalents, and marketable securities
  2. Completed rolling Biologics License Application submission to FDA for nomlabofusp

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Larimar Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.